 BOSTON--BUSINESS WIRE--Verastem, Inc. Nasdaq:VSTM also known as Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the initiation of a Phase 2 registration-directed clinical trial of VS-6766, its RAFMEK inhibitor, and defactinib, its FAK inhibitor, in patients with recurrent low-grade serous ovarian cancer LGSOC. Results to date have demonstrated the clinical activity of VS-6766 and defactinib in KRAS mutan 